“敢”的底气——探寻中关村生命科学园打造生命科学新高地的时代脉动

Core Insights - The Beijing Zhongguancun Life Science Park has transformed into a vital axis for Beijing's international technology innovation center, becoming a key base for life sciences, biotechnology, and new pharmaceutical industries in China [1][3] - The park has developed a vibrant industrial ecosystem with hundreds of pharmaceutical companies, supported by favorable policies and capital, creating a "biopharmaceutical rainforest" [1][3] Innovation Chain - The park features a comprehensive innovation chain that includes basic research, technology development, clinical validation, and production sales, exemplified by institutions like the National Protein Science Center [2][3] - Key research institutions and hospitals within the park facilitate the transition from scientific discovery to practical applications in medicine [2] Industry Ecosystem - Over 600 innovative pharmaceutical companies, including BeiGene and Innovent Biologics, are located in the park, focusing on transforming research findings into potential new drug candidates [3][4] - The park has evolved from being policy-driven to a self-driven industry ecosystem, showcasing a mature life sciences innovation environment [3] Achievements and Recognition - The park has produced significant innovations, including China's first billion-dollar drug, Zebutine, and has been recognized as the top life sciences park in China according to a report by the China Biotechnology Development Center [4][8] - The park's unique advantages include a strong industrial foundation, natural clustering effects, and a complete industrial chain, supported by top research institutions and talent reserves in Beijing [4] Entrepreneurial Environment - The park is described as an "ideal paradise" for scientists, with many researchers becoming entrepreneurs, leading to the establishment of 112 companies founded by scientists [5][6] - The support for early-stage scientific entrepreneurship is a key attraction of the Zhongguancun Life Science Park, providing essential resources and funding [6][7] Funding and Investment - The Beijing government has established a 20 billion yuan pharmaceutical health industry investment fund to support the development of the industry [8] - The park's operational platform has partnered with over 50 market-oriented investment funds, investing in 468 pharmaceutical health projects to empower original innovations [8] Future Development - The 2024 Beijing Action Plan emphasizes the importance of building research hospitals and accelerating the construction of the Zhongguancun Life Science Park's third phase to enhance its global competitiveness [9][10] - The park aims to maintain its leading position in emerging fields such as cell and gene therapy, with a focus on platform construction to support industry development [10][12]